Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease

Significance An expanding body of evidence argues that the Aβ and tau proteins share important characteristics of prion propagation to cause pathogenesis in Alzheimer’s disease (AD). Aβ and tau form a number of amyloids (β-sheet–rich structures) with distinct conformations (“strains”), some of which give rise to different diseases and associated pathologies. We develop new probes of amyloid structure and use these to identify conformational strains of Aβ in heritable and sporadic forms of AD patient samples. We demonstrate that distinct strains of Aβ can be discerned in different disease types, or in different brain compartments within a given patient. Our findings may potentially explain the spectrum of clinical and pathologic features observed in AD. Point mutations in the amyloid-β (Aβ) coding region produce a combination of mutant and WT Aβ isoforms that yield unique clinicopathologies in familial Alzheimer’s disease (fAD) and cerebral amyloid angiopathy (fCAA) patients. Here, we report a method to investigate the structural variability of amyloid deposits found in fAD, fCAA, and sporadic AD (sAD). Using this approach, we demonstrate that mutant Aβ determines WT Aβ conformation through prion template-directed misfolding. Using principal component analysis of multiple structure-sensitive fluorescent amyloid-binding dyes, we assessed the conformational variability of Aβ deposits in fAD, fCAA, and sAD patients. Comparing many deposits from a given patient with the overall population, we found that intrapatient variability is much lower than interpatient variability for both disease types. In a given brain, we observed one or two structurally distinct forms. When two forms coexist, they segregate between the parenchyma and cerebrovasculature, particularly in fAD patients. Compared with sAD samples, deposits from fAD patients show less intersubject variability, and little overlap exists between fAD and sAD deposits. Finally, we examined whether E22G (Arctic) or E22Q (Dutch) mutants direct the misfolding of WT Aβ, leading to fAD-like plaques in vivo. Intracerebrally injecting mutant Aβ40 fibrils into transgenic mice expressing only WT Aβ induced the deposition of plaques with many biochemical hallmarks of fAD. Thus, mutant Aβ40 prions induce a conformation of WT Aβ similar to that found in fAD deposits. These findings indicate that diverse AD phenotypes likely arise from one or more initial Aβ prion conformations, which kinetically dominate the spread of prions in the brain.

[1]  N. Fox,et al.  Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions , 2017, Cell.

[2]  S. Prusiner,et al.  A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells. , 2017, Nature chemistry.

[3]  John Collinge,et al.  Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes , 2016, Nature.

[4]  N. Cairns,et al.  Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer’s Disease , 2016, Scientific Reports.

[5]  S. Prusiner,et al.  Structural Polymorphism of Alzheimer's β-Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study. , 2016, Journal of the American Chemical Society.

[6]  Judianne Davis,et al.  Cerebral vascular amyloid seeds drive amyloid β-protein fibril assembly with a distinct anti-parallel structure , 2016, Nature Communications.

[7]  G. Antoni,et al.  Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.

[8]  Nick C Fox,et al.  Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease , 2015, The Journal of experimental medicine.

[9]  S. Guan,et al.  Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[10]  A. Fagan,et al.  Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease , 2015, Neurology.

[11]  Mathias Jucker,et al.  Neurodegenerative diseases: expanding the prion concept. , 2015, Annual review of neuroscience.

[12]  J. Haines,et al.  Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. , 2015, Brain : a journal of neurology.

[13]  J. Grutzendler,et al.  Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques , 2014, Nature Communications.

[14]  R. Glockshuber,et al.  Atomic-Resolution Three-Dimensional Structure of Amyloid β Fibrils Bearing the Osaka Mutation , 2014, Angewandte Chemie.

[15]  D. Selkoe,et al.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. , 2014, Human molecular genetics.

[16]  S. Prusiner,et al.  Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice , 2014, Proceedings of the National Academy of Sciences.

[17]  S. Prusiner,et al.  Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients , 2014, Proceedings of the National Academy of Sciences.

[18]  L. Grinberg,et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.

[19]  Ping Zhou,et al.  Age-Dependent Neurovascular Dysfunction and Damage in a Mouse Model of Cerebral Amyloid Angiopathy , 2014, Stroke.

[20]  H. Arai,et al.  Use of a Benzimidazole Derivative BF-188 in Fluorescence Multispectral Imaging for Selective Visualization of Tau Protein Fibrils in the Alzheimer’s Disease Brain , 2014, Molecular Imaging and Biology.

[21]  J. Clarimón,et al.  Autosomal‐dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production , 2014, Journal of neurochemistry.

[22]  Judianne Davis,et al.  Cerebral microvascular rather than parenchymal amyloid-β protein pathology promotes early cognitive impairment in transgenic mice. , 2013, Journal of Alzheimer's disease : JAD.

[23]  K. Nilsson,et al.  Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice , 2013, EMBO reports.

[24]  S. Prusiner,et al.  Drug resistance confounding prion therapeutics , 2013, Proceedings of the National Academy of Sciences.

[25]  G. Schellenberg,et al.  The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ , 2013, Acta neuropathologica communications.

[26]  M. Takeda,et al.  γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. , 2013, Cell reports.

[27]  M. Freedman,et al.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.

[28]  J. Castilla,et al.  De novo induction of amyloid-β deposition in vivo , 2012, Molecular Psychiatry.

[29]  H. Wenschuh,et al.  A comparative analysis of the aggregation behavior of amyloid‐β peptide variants , 2012, FEBS letters.

[30]  B. Ghetti,et al.  APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38 , 2012, Acta Neuropathologica.

[31]  R. Nitsch,et al.  Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation , 2012, Translational Psychiatry.

[32]  A. Wall,et al.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.

[33]  S. Prusiner,et al.  A Unifying Role for Prions in Neurodegenerative Diseases , 2012, Science.

[34]  Stephen J. DeArmond,et al.  Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.

[35]  M. Lalowski,et al.  The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ , 2012, Neurobiology of Aging.

[36]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[37]  R. Leigh,et al.  Treatable neurological disorders misdiagnosed as Creutzfeldt‐Jakob disease , 2011, Annals of neurology.

[38]  R. Tycko,et al.  The Japanese mutant Aβ (ΔE22-Aβ(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Aβ(1-40) into atypical fibrils by ΔE22-Aβ(1-39). , 2011, Biochemistry.

[39]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[40]  A. Bizzi,et al.  Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. , 2010, Archives of neurology.

[41]  M. Gearing,et al.  Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease , 2010, Acta Neuropathologica.

[42]  David W. Colby,et al.  Design and construction of diverse mammalian prion strains , 2009, Proceedings of the National Academy of Sciences.

[43]  Martin L. Duennwald,et al.  A synergistic small molecule combination directly eradicates diverse prion strain structures , 2009, Nature chemical biology.

[44]  R. Leapman,et al.  Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure , 2009, Proceedings of the National Academy of Sciences.

[45]  M. Staufenbiel,et al.  E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. , 2009, The American journal of pathology.

[46]  J. Wiltfang,et al.  Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase* , 2008, Journal of Biological Chemistry.

[47]  B. Ghetti,et al.  Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene] , 2008, FEBS letters.

[48]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[49]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[50]  Richard M. Page,et al.  Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation* , 2008, Journal of Biological Chemistry.

[51]  Jonathan S. Weissman,et al.  The structural basis of yeast prion strain variants , 2007, Nature.

[52]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[53]  Judianne Davis,et al.  Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double Aß in human AßPP transgenic mice , 2006, Neurobiology of Aging.

[54]  Irene Otte-Höller,et al.  Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. , 2005, The American journal of pathology.

[55]  Lingyun Zhu,et al.  Non-invasive imaging of GFAP expression after neuronal damage in mice , 2004, Neuroscience Letters.

[56]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Lansbury,et al.  Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. , 2003, Journal of molecular biology.

[58]  R. Roos,et al.  Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles , 2001, Annals of neurology.

[59]  T D Bird,et al.  Neuropathological heterogeneity in Alzheimer’s disease: A study of 80 cases using principal components analysis , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[60]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[61]  E. Storey,et al.  The D178N (cis-129M) "fatal familial insomnia" mutation associated with diverse clinicopathologic phenotypes in an Australian kindred , 1997, Neurology.

[62]  S. Prusiner,et al.  Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity , 1996, Science.

[63]  S. Prusiner,et al.  Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. , 1996, Genes & development.

[64]  J. Hauw,et al.  BSE transmission to macaques , 1996, Nature.

[65]  J. Growdon,et al.  Transmission and age-at-onset patterns in familial Alzheimer??s disease: evidence for heterogeneity , 1991 .

[66]  S. M. Sumi,et al.  Phenotypic heterogeneity in familial alzheimer's disease: A study of 24 kindreds , 1989, Annals of neurology.

[67]  A. Paetau,et al.  Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. , 2014, Journal of Alzheimer's disease : JAD.

[68]  J. Laplanche,et al.  Rapidly progressive Alzheimer's disease: a multicenter update. , 2012, Journal of Alzheimer's disease : JAD.

[69]  B. Ghetti,et al.  Neocortical variation of Abeta load in fully expressed, pure Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[70]  Richard M. Page,et al.  Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. , 2008, The Journal of biological chemistry.

[71]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[72]  C. Merril,et al.  A rapid sensitive silver stain for polypeptides in polyacrylamide gels. , 1981, Analytical biochemistry.

[73]  A. Rowan Guide for the Care and Use of Laboratory Animals , 1979 .